SKYE
NASDAQ
US
Skye Bioscience, Inc. - Common Stock
$0.70
▲ +$0.03
(+4.96%)
Vol 210K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$24.0M
ROE
-100.5%
Margin
-3.6%
D/E
0.00
Beta
2.81
52W
$1–$6
Wall Street Consensus
14 analysts · Apr 20264
Strong Buy
7
Buy
3
Hold
0
Sell
0
Strong Sell
78.6%
Buy Rating
Price Chart
Similar Stocks
BOLD
Boundless Bio Inc
$26.9M
CYCN
Cyclerion Therapeutics Inc
$5.0M
NEUP
Neuphoria Therapeutics Inc
$20.9M
LGVN
Longeveron Inc
$10.8M
VTGN
Vistagen Therapeutics Inc
$26.1M
SNTI
Senti Biosciences Inc
$27.3M
MRKR
Marker Therapeutics Inc
$24.8M
CRIS
Curis Inc
$12.8M
TPST
Tempest Therapeutics Inc
$14.1M
Earnings
Beat rate: 50.0%
Next Report
May 06, 2026
EPS Estimate: $-0.32
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.32 | — | — |
| Dec 2025 | $-0.30 | $-0.36 | $-0.06 |
| Sep 2025 | $-0.34 | $-0.32 | +$0.02 |
| Jun 2025 | $-0.32 | $-2.69 | $-2.37 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -68.7% | -68.7% | -68.7% | -68.7% | -100.5% | -100.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -3.6% | -3.6% | -3.6% | -3.6% | -3.6% |
| Gross Margin | — | 39.3% | 39.3% | 39.3% | 39.3% | 39.3% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 6.09 | 6.09 | 6.09 | 6.09 | 4.77 | 4.77 |
Key Ratios
ROA (TTM)
-88.7%
P/S (TTM)
85.83
P/B
1.3
EPS (TTM)
$-1.29
CF/Share
$-9.31
52W High
$5.75
52W Low
$0.76
$0.76
52-Week Range
$5.75
How does SKYE compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
SKYE valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
85.8
▲
568%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
1.3
▼
49%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
SKYE profitability vs Biotechnology peers
ROE
-100.5%
▼
49%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-3.6%
▲
99%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
39.3%
▼
50%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-88.7%
▼
90%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
SKYE financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
4.8
▲
7%
above
peers
(4.4)
vs Peers
vs Industry
In line
Beta
2.8
▲
189%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
SKYE fundamentals radar
SKYE
Peer median
Industry
SKYE profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
SKYE vs peers: key metrics
Latest News
No related news yet